Cohort I (n = 453) | Cohort II (n = 1201) | |
---|---|---|
Females, % | 73.1 | 76.8 |
Mean age, years | 65.6 ± 14.5a | 46.5 ± 14.5a |
Duration of follow-up, months | 123.8 ± 91.5a | 171.6 ± 123.6a |
Extraarticular manifestations, % | 22.2 | – |
Presence of joint damage, % | – | 100 |
RF-positive, % | 64.8 | 74.6 |
ACPA-positive, % | 62.2 | 74.1 |
Number of previous DMARDs | 2.2 ± 1.5a | 1.7 ± 1.5a |
Number of previous biologic therapies | 1.8 ± 1.2a | 0.6 ± 0.9a |